

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2017/100542 A8

(43) International Publication Date
15 June 2017 (15.06.2017)

(51) International Patent Classification:
C12N 15/113 (2010.01) A61P 3/06 (2006.01)
A61K 31/713 (2006.01)

(21) International Application Number:
PCT/US2016/065781

(22) International Filing Date:
9 December 2016 (09.12.2016)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/265,580 10 December 2015 (10.12.2015) US
62/378,964 24 August 2016 (24.08.2016) US

(71) Applicant: ALNYLAM PHARMACEUTICALS, INC.
[US/US]; 300 Third Street, 3rd Floor, Cambridge, MA
02142 (US).

(72) Inventors: FITZGERALD, Kevin; 300 Third Street, 3rd
Floor, Cambridge, MA 02142 (US). XU, Huilei; 300 Third
Street, 3rd Floor, Cambridge, MA 02142 (US). HINKLE,
Gregory; 300 Third Street, 3rd Floor, Cambridge, MA
02142 (US).

(74) Agents: ZACHARAKIS, Maria Laccotripe et al.; Mc-
Carter & English, LLP, 265 Franklin Street, Boston, MA
02110 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,

MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,
TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(48) Date of publication of this corrected version:
13 July 2017

(15) Information about Correction:
see Notice of 13 July 2017

(54) Title: STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

(57) Abstract: The invention relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting the SCAP gene, as well as methods of inhibiting expression of a SCAP gene and methods of treating subjects having a SCAP-associated disorder, such as nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH), using such dsRNAi agents and compositions.



WO 2017/100542 A8